Plus Therapeutics, INC 8-K filings

Plus Therapeutics, Inc. has entered into a Securities Purchase and Exchange Agreement, raising approximately $3.7 million through the issuance of secured convertible promissory notes and warrants, while also exchanging existing warrants to streamline its capital structure.

Plus Therapeutics reported its Q3 2024 financial results, highlighted by progress in clinical trials and strategic partnerships.

Plus Therapeutics has been granted an extension until March 4, 2025, to meet Nasdaq's minimum stockholders' equity requirement.

Plus Therapeutics has received a delisting notice from Nasdaq due to not meeting the minimum stockholders' equity requirement, and the company plans to appeal the decision.

Plus Therapeutics held its 2024 Annual Meeting of Stockholders on August 15, 2024, where shareholders elected directors, ratified the appointment of an accounting firm, and approved executive compensation and a stock incentive plan amendment.

Plus Therapeutics reported positive interim data for its ReSPECT-LM Phase 1 trial and topline results for its CNSide diagnostic test, alongside its second quarter 2024 financial results.

Plus Therapeutics, Inc. announced the resignation of its Chief Medical Officer, Dr. Norman LaFrance, effective June 12, 2024.

Plus Therapeutics drew $3.3 million from its margin loan facility to fully repay its existing term loan with Oxford Finance, LLC.

Plus Therapeutics has announced its 2024 Annual Meeting of Stockholders will be held virtually on August 15, 2024, with a record date of June 25, 2024.

Plus Therapeutics reported its Q1 2024 financial results, highlighted by a $19.25 million private placement, a $3 million Department of Defense grant, and the acquisition of a leptomeningeal metastases diagnostic portfolio.

Plus Therapeutics has successfully raised approximately $7.25 million through a private placement of common stock and warrants, with potential for an additional $12 million from warrant exercises.

Plus Therapeutics has received a notice from Nasdaq for failing to maintain the minimum stockholders' equity requirement for continued listing.

Plus Therapeutics highlighted its targeted radiotherapeutic platform for central nervous system cancers, showcasing encouraging clinical trial results and upcoming milestones.

Plus Therapeutics announced its full year 2023 financial results, highlighted clinical trial progress, and outlined key objectives for 2024, including plans to advance its lead radiotherapeutic into registrational trials in 2025.